Responsiveness of classical kaposi's sarcoma to recombinant interferon alpha 2b treatment

M. Monti, M. Barbareschi, A. Angius, R. Caputo

Research output: Contribution to journalArticlepeer-review

Abstract

Low doses of recombinant interferon alpha 2b were used to treat two patients with Kaposi's sarcoma not associated with AIDS. Clinical benefit was obtained after a few months in both cases. In one case dynamic telethermography demonstrated regression of the disease after 9 months of treatment. No serious side-effects were observed during interferon administration. We conclude that recombinant interferon alpha 2b could be considered a treatment of choice for Kaposi's sarcoma not associated with AIDS.

Original languageEnglish
Pages (from-to)209-210
Number of pages2
JournalJournal of Dermatological Treatment
Volume1
Issue number4
DOIs
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Responsiveness of classical kaposi's sarcoma to recombinant interferon alpha 2b treatment'. Together they form a unique fingerprint.

Cite this